Trending NewsTrending NewsNASDAQ:ACIU AC Immune (ACIU) Stock Price, News & Analysis $2.14 +0.06 (+2.88%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$2.17 +0.03 (+1.40%) As of 08/8/2025 05:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About AC Immune Stock (NASDAQ:ACIU) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get AC Immune alerts:Sign Up Key Stats Today's Range$2.07▼$2.1950-Day Range$1.65▼$2.4552-Week Range$1.43▼$3.98Volume97,918 shsAverage Volume163,494 shsMarket Capitalization$214.88 millionP/E RatioN/ADividend YieldN/APrice Target$12.00Consensus RatingBuy Company Overview AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland. Read More AC Immune Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks40th Percentile Overall ScoreACIU MarketRank™: AC Immune scored higher than 40% of companies evaluated by MarketBeat, and ranked 679th out of 925 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingAC Immune has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageAC Immune has received no research coverage in the past 90 days.Read more about AC Immune's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for AC Immune are expected to grow in the coming year, from ($0.62) to ($0.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AC Immune is -3.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AC Immune is -3.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAC Immune has a P/B Ratio of 2.38. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted2.29% of the float of AC Immune has been sold short.Short Interest Ratio / Days to CoverAC Immune has a short interest ratio ("days to cover") of 10.5, which indicates bearish sentiment.Change versus previous monthShort interest in AC Immune has recently decreased by 0.71%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAC Immune does not currently pay a dividend.Dividend GrowthAC Immune does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.29% of the float of AC Immune has been sold short.Short Interest Ratio / Days to CoverAC Immune has a short interest ratio ("days to cover") of 10.5, which indicates bearish sentiment.Change versus previous monthShort interest in AC Immune has recently decreased by 0.71%, indicating that investor sentiment is improving. News and Social Media1.9 / 5News Sentiment0.42 News SentimentAC Immune has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 20 news articles for AC Immune this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for ACIU on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, AC Immune insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.60% of the stock of AC Immune is held by insiders.Percentage Held by Institutions51.36% of the stock of AC Immune is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about AC Immune's insider trading history. Receive ACIU Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AC Immune and its competitors with MarketBeat's FREE daily newsletter. Email Address ACIU Stock News HeadlinesAC Immune Reports Q2 2025 Financial ProgressAugust 8 at 12:15 AM | tipranks.comAC Immune SA Reports Increased Losses in Mid-2025 Financial ResultsAugust 5, 2025 | tipranks.comElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social Security? What we just discovered in Washington will stun even the most seasoned insiders.August 9 at 2:00 AM | Banyan Hill Publishing (Ad)AC Immune SA Reports Q2 2025 Financial Results and Advancements in Neurodegenerative Disease TherapiesAugust 5, 2025 | quiverquant.comQAC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate UpdateAugust 5, 2025 | globenewswire.comACIU AC Immune SA - Seeking AlphaJune 29, 2025 | seekingalpha.comAC Immune SA (ACIU) - Yahoo FinanceJune 27, 2025 | finance.yahoo.comAC Immune Ltd Analysis & Opinion (ACIU) - Investing.comJune 25, 2025 | investing.comSee More Headlines ACIU Stock Analysis - Frequently Asked Questions How have ACIU shares performed this year? AC Immune's stock was trading at $2.70 at the beginning of the year. Since then, ACIU stock has decreased by 20.7% and is now trading at $2.14. How were AC Immune's earnings last quarter? AC Immune (NASDAQ:ACIU) issued its quarterly earnings data on Tuesday, August, 5th. The company reported ($0.25) earnings per share for the quarter, missing analysts' consensus estimates of ($0.20) by $0.05. The business earned $1.65 million during the quarter, compared to analyst estimates of $1.98 million. AC Immune had a negative trailing twelve-month return on equity of 49.35% and a negative net margin of 174.94%. When did AC Immune IPO? AC Immune (ACIU) raised $55 million in an initial public offering (IPO) on Friday, September 23rd 2016. The company issued 4,600,000 shares at a price of $11.00-$13.00 per share. Credit Suisse, Jefferies and Leerink Partners acted as the underwriters for the IPO. How do I buy shares of AC Immune? Shares of ACIU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of AC Immune own? Based on aggregate information from My MarketBeat watchlists, some other companies that AC Immune investors own include Meta Platforms (META), NVIDIA (NVDA), Corbus Pharmaceuticals (CRBP), Sorrento Therapeutics (SRNE), Tesla (TSLA), Advanced Micro Devices (AMD) and Canopy Growth (CGC). Company Calendar Last Earnings8/05/2025Today8/09/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ACIU CIK1651625 Webwww.acimmune.com Phone(121) 345-9121Fax41-21-345-9120Employees140Year FoundedN/APrice Target and Rating Average Price Target for AC Immune$12.00 High Price Target$12.00 Low Price Target$12.00 Potential Upside/Downside+460.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)($0.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$57.83 million Net Margins-174.94% Pretax Margin-176.80% Return on Equity-49.35% Return on Assets-23.16% Debt Debt-to-Equity RatioN/A Current Ratio1.33 Quick Ratio1.53 Sales & Book Value Annual Sales$31.02 million Price / Sales6.93 Cash FlowN/A Price / Cash FlowN/A Book Value$0.90 per share Price / Book2.38Miscellaneous Outstanding Shares100,410,000Free Float95,791,000Market Cap$214.88 million OptionableOptionable Beta1.65 The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:ACIU) was last updated on 8/9/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AC Immune Please log in to your account or sign up in order to add this asset to your watchlist. Share AC Immune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.